Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Analysts

Structure Therapeutics Inc. (NASDAQ:GPCR) has received a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $86.80.

A number of brokerages have recently commented on GPCR. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, September 23rd. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target for the company. Finally, JMP Securities cut their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $33.74 on Wednesday. Structure Therapeutics has a fifty-two week low of $26.61 and a fifty-two week high of $66.38. The company has a market capitalization of $1.93 billion, a PE ratio of -45.59 and a beta of -3.23. The stock has a fifty day moving average of $38.58 and a two-hundred day moving average of $39.50.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of GPCR. RA Capital Management L.P. increased its holdings in Structure Therapeutics by 210.2% in the 1st quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after purchasing an additional 1,023,530 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Structure Therapeutics by 196.5% in the third quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after buying an additional 820,589 shares during the period. Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics by 18.0% in the third quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after buying an additional 590,000 shares during the period. Finally, Capital Research Global Investors lifted its position in Structure Therapeutics by 56.9% during the 1st quarter. Capital Research Global Investors now owns 1,527,483 shares of the company’s stock worth $65,468,000 after acquiring an additional 553,948 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.